HEPATIC ARTERIAL CHEMOEMBOLIZATION FOR METASTATIC NEUROENDOCRINE TUMORS

Purpose of the study. To evaluate the effectiveness of chemoembolizati on of the liver with doxorubicin and iopamidol emulsified in ethiodize d oil for the treatment of metastatic neuroendocrine tumors. Patients and methods. Twenty patients with hepatic islet cell or carcinoid meta stases were treated with selected hepatic arterial embolization consis ting of an emulsion of doxorubicin and iopamidol emulsified in ethiodo l followed by Gelfoam powder embolization. Fifteen patients had failed intravenous chemotherapy. Two of the patients with carcinoid tumors h ad three embolizations over 4 and one 6 years earlier with gelatin spo nge only. Results. In 14 patients with hormonally active tumors, hormo nes secretion decreased 90% (range 69-98%) in 10 days with relief of s ymptoms in all patients. Average tumor size decrease was 84%. Average hospital stay was 8 days. Six patients are alive and asymptomatic at 1 4-33 months post-embolization. Fourteen patients have died 2-16 months postembolization. Ten patients died 2-37 months postembolization from progressive liver disease. One of these patients was 103 months post- Gelfoam embolization and 13 months postchemoembolization. In 8 patient s, the pancreas was the primary site: 5 were nonfunctioning islet cell carcinomas, 1 glucagonoma, 1 gastrinoma and 1 carcinoid. The primary site in 1 patient with carcinoid was the bronchus, and the primary sit e was unknown in 1 patient with gastrinoma. The remaining 4 patients d ied with liver disease under control from renal failure, peritonitis, carcinoid heart failure and generalized bone metastases. The response rate was 95% with median duration of response 8.5 months. The median s urvival was 24 months. Conclusion. Chemoembolization with doxorubicin and iopamidol emulsified in ethiodized oil is less morbid than emboliz ation with particulate matter alone, is more convenient and less costl y, and it is less morbid than the effects of systemic chemotherapy. Th e median survival, duration and response compare favorably with other reported therapies.